Every Form 4 that Pyxis Oncology, Inc. (PYXS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PYXS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PYXS filings page.
Pyxis Oncology, Inc. (PYXS) reported that CEO and Chairman Thomas Civik received a grant of stock options covering 2,503,050 shares of common stock on September 4, 2026. The options have an exercise price of $3.89 per share and expire on September 4, 2036. The award vests over four years, with 25% vesting on the first anniversary of September 4, 2026 and the remainder vesting in 36 equal monthly installments, subject to his continued employment. No Rule 10b5-1 trading plan is reported for this award.
Pyxis Oncology, Inc. (PYXS) reported that director Jakob Dupont received a grant of 46,000 stock options on August 20, 2026. The options have an exercise price of $3.12 per share, expire on August 20, 2036, and will vest in equal monthly installments through October 31, 2026, subject to his continued service. Following this award, he holds 46,000 options directly.
Pyxis Oncology, Inc. reported that Interim CEO and director Thomas Civik acquired a performance-based stock option covering 250,956 shares of common stock. The option, with an exercise price of $1.49 per share and expiration on February 3, 2036, became vested in full on August 12, 2026 after the Board determined that performance conditions tied to a successful financing or strategic transaction had been met. Following this grant, Civik directly holds options for 941,087 shares.
Pyxis Oncology director Jakob Dupont reported an exercise-and-sale of company stock. He exercised stock options covering 35,000 shares of common stock at an exercise price of $1.60 per share and received the underlying shares.
On the same date, he sold 35,000 common shares in open-market transactions at a weighted average price of $3.06 per share, with trade prices ranging from $3.00 to $3.36. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan. After the transactions, Dupont holds 38,741 shares of Pyxis Oncology common stock directly.
Pyxis Oncology director Jakob Dupont received a new stock option grant. The award covers 45,867 options to buy Common Stock at an exercise price of $1.36 per share, expiring on March 24, 2036. All of these options vest 100% on the first anniversary of the grant date, contingent on his continued service. Following this grant, Dupont holds 45,867 derivative securities, reflecting a routine, compensation-related equity award rather than an open‑market trade.
Pyxis Oncology, Inc. reported that principal financial and accounting officer Jitendra Wadhane received new equity compensation awards. He was granted a stock option for 262,635 shares of common stock at an exercise price of $1.36 per share, expiring on March 24, 2036. He also received 109,461 shares of common stock in the form of restricted stock units at no cost.
The restricted stock units vest 25% on March 31, 2026, then in 36 substantially equal monthly installments, subject to continued employment. The stock option vests 25% on the first anniversary of March 24, 2026, with the remainder vesting in 36 equal monthly installments on continued employment. Following these awards, his directly held common stock position is 512,882 shares.
Pyxis Oncology, Inc. reported that director John L. Flavin received a grant of stock options covering 45,867 shares of common stock. The options have an exercise price of $1.36 per share and expire on March 24, 2036. According to the terms, 100% of these options vest on the first anniversary of the grant date, subject to his continued service, and following this grant he holds 45,867 derivative securities directly.
Pyxis Oncology director Michael A. Metzger received a grant of 45,867 stock options for Common Stock. The options have an exercise price of $1.3600 per share and expire on March 24, 2036. All 45,867 options vest 100% on the first anniversary of the grant date, contingent on his continued service.
Following this award, Metzger holds 45,867 options directly, and no open-market purchases or sales were reported in this filing.
Pyxis Oncology director Freda C. Lewis-Hall received a stock option award for 45,867 shares of common stock. The option has an exercise price of $1.36 per share and expires on March 24, 2036. According to the filing, all 45,867 option shares will vest 100% on the first anniversary of the grant date, if she continues in service through that vesting date. Following this grant, she holds 45,867 stock options directly.
Pyxis Oncology director Darren S. Cline received a stock option grant for 45,867 shares of Common Stock. The option has an exercise price of $1.36 per share and expires on March 24, 2036. All 45,867 option shares vest 100% on the first anniversary of the grant date, contingent on his continued service. Following this grant, Cline holds options covering 45,867 shares, and the filing shows no same-day exercises or market purchases or sales.
Pyxis Oncology, Inc. director Rachel Humphrey received a grant of stock options covering 45,867 shares of common stock. The options have an exercise price of $1.36 per share and were awarded at no cost to her.
The filing states that all 45,867 options will vest 100% on the first anniversary of the March 24, 2026 grant date, as long as she continues in service through that date. Following this award, her reported derivative holdings from this grant total 45,867 stock options.
Pyxis Oncology, Inc. director Palani Santhosh received a grant of stock options covering 45,867 shares of common stock. The options carry an exercise price of $1.36 per share and expire on March 24, 2036. All 45,867 options will vest 100% on the first anniversary of the grant date, conditioned on his continued service through that vesting date. Following this grant, he holds 45,867 stock options directly.
Pyxis Oncology director Rachel Humphrey reported open-market sales of a total of 15,496 shares of Pyxis Oncology common stock. The sales occurred on April 14, 17, and 21, 2025 at prices of $0.9727, $0.97, and $1.0335 per share, respectively.
The filing notes these transactions were executed under a Rule 10b5-1 trading plan adopted on December 5, 2024, indicating they were pre-scheduled. Following the latest sale, Humphrey directly holds 81,309 shares of Pyxis Oncology common stock.
Pyxis Oncology, Inc. reported that Interim Chief Executive Officer and director Thomas Civik received a new stock option grant. On February 3, 2026, he was awarded an option to purchase 690,131 shares of common stock at an exercise price of $1.49 per share, expiring on February 3, 2036.
The option vests in 12 equal monthly installments, starting on the grant date, and each monthly vesting is conditioned on his continued service as Interim Chief Executive Officer through the applicable vesting date. Following this grant, he beneficially owns 690,131 derivative securities directly in the form of this option.